Canabinoides sintéticos (cs) - novas drogas, novos riscos
Conteúdo do artigo principal
Resumo
Os canabinoides sintéticos (CS) compõem um grupo crescente das assim chamadas “designer drugs”. Seu consumo tem aumentado em muitos países, inclusive o Brasil, com a expansão do comércio ilegal e a falsa percepção entre os jovens de que são compostos “naturais” ou “legais”. Contribui para esse cenário a dificuldade de detecção desses novos compostos em testes de triagem convencionais. São abordadas neste artigo as principais manifestações clínicas e toxicológicas do uso dos CS. Atenção especial é dada a alguns riscos do uso desses produtos, incluindo alucinações, psicose, estados confusionais, convulsões, sintomas cardiovasculares, lesão renal e lesão pulmonar. O pediatra que atende adolescentes deve estar atento para o diagnóstico e manejo correto das novas situações de risco.
Downloads
Detalhes do artigo
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Referências
1. Castellanos D, Leonard M Gralnik.Synthetic Cannabinoids 2015: An update for pediatricians in clinical practice,World JClin Pediatr 2016 February 8;5(1):16-24
2. Antoniou, Tony. Juurlink, David N. Synthetic Cannabinoids, five things to know about. CMAJ, February 18,2014,186(3)
3. Alper A, Akdam H, Yilmaz A, Ersan S. Synthetic Cannabinoids in the Kidneys.Rev Assoc Med Bras 2017;63(1):10-12.
4. Musselman ME, Hampton JP. "Not for human consumption": a review of emerging designer drugs. Pharmacotherapy 2014; 34:745.
5. Nelson ME, Bryant SM, Aks SE. Emerging drugs of abuse. Emerg Med Clin North Am 2014; 32:1.
6. Kuehn B. Synthetic Cannabidiol Poisoning. JAMA 2018; 319:2264.
7. Adams AJ, Banister SD, Irizarry L, et al. "Zombie" Outbreak Caused by the Synthetic Cannabinoid AMB-FUBINACA in New York. N Engl J Med 2017; 376:235.
8. Trecki J, Gerona RR, Schwartz MD. Synthetic Cannabinoid-Related Illnesses and Deaths. N Engl J Med 2015; 373:103.
9. Wood KE. Exposure to bath salts and synthetic tetrahydrocannabinol from 2009 to 2012 in the United States. J Pediatr 2013; 163:213.
10. Monte AA, Bronstein AC, Cao DJ, et al. An outbreak of exposure to a novel synthetic cannabinoid. N Engl J Med 2014; 370:389.
11. Kemp AM, Clark MS, Dobbs T, et al. Top 10 Facts You Need to Know About Synthetic Cannabinoids: Not So Nice Spice. Am J Med 2016;129:240.
12. Palamar JJ, Barratt MJ, Coney L, Martins SS. Synthetic Cannabinoid Use Among High School Seniors. Pediatrics 2017; 140.
13. Ammann J, McLaren JM, Gerostamoulos D, Beyer J. Detection and quantification of new designer drugs in human blood: Part 1 - Synthetic cannabinoids. J Anal Toxicol 2012; 36:372.
14. Fantegrossi WE, Moran JH, Radominska-Pandya A, Prather PL. Distinct pharmacology and metabolism of K2 synthetic cannabinoidscompared to Δ(9)-THC: mechanism underlying greater toxicity? Life Sci 2014; 97:45.
15. Rajasekaran M, Brents LK, Franks LN, et al. Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. Toxicol Appl Pharmacol 2013; 269:100.
16. Potts AJ, Cano C, Thomas SHL, Hill SL. Synthetic cannabinoid receptor agonists: classification and nomenclature. Clin Toxicol (Phila) 2020; 58:82.
17. Anderson SAR, Oprescu AM, Calello DP, et al. Neuropsychiatric Sequelae in Adolescents With Acute Synthetic Cannabinoid Toxicity. Pediatrics 2019; 144.
18. Seywright A, Torrance HJ, Wylie FM, et al. Analysis and clinical findings of cases positive for the novel synthetic cannabinoid receptoragonist MDMB-CHMICA. Clin Toxicol (Phila) 2016; 54:632.
19. Hill SL, Najafi J, Dunn M, et al. Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMBCHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study. Clin Toxicol (Phila) 2016; 54:638.
20. Clark BC, Georgekutty J, Berul CI. Myocardial Ischemia Secondary to Synthetic Cannabinoid (K2) Use in Pediatric Patients. J Pediatr 2015;167:757.
21. Rose DZ, Guerrero WR, Mokin MV, et al. Hemorrhagic stroke following use of the synthetic marijuana "spice". Neurology 2015; 85:1177.
22. Buser GL, Gerona RR, Horowitz BZ, et al. Acute kidney injury associated with smoking synthetic cannabinoid. Clin Toxicol (Phila) 2014;52:664.
23. Connors JM. Hemorrhagic Highs from Synthetic Cannabinoids - A New Epidemic. N Engl J Med 2018; 379:1275.
24. Gotts JE, Jordt SE, McConnell R, Tarran R. What are the respiratory effects of e- cigarettes? BMJ 2019; 366:l5275.
25. Triantafyllou GA, Tiberio PJ, Zou RH, et al. Vaping-associated Acute Lung Injury: A Case Series. Am J Respir Crit Care Med 2019; 200:1430.
26. Layden JE, Ghinai I, Pray I, et al. Pulmonary Illness Related to E-Cigarette Use in Illinois and Wisconsin - Final Report. N Engl J Med 2020; 382:903.
27. 27 Kligerman S, Raptis C, Larsen B, et al. Radiologic, Pathologic, Clinical, and Physiologic Findings of Electronic Cigarette or Vaping Product Use-associated Lung Injury (EVALI):Evolving Knowledge and Remaining Questions. Radiology 2020; 294:491.
28. Hswen Y, Brownstein JS. Real-Time Digital Surveillance of Vaping-Induced PulmonaryDisease. N Engl J Med 2019; 381:1778.
29. Jonas AM, Raj R. Vaping-Related Acute Parenchymal Lung Injury: A Systematic Review. Chest 2020; 158:1555.
30. Hartnett KP, Kite-Powell A, Patel MT, et al. Syndromic Surveillance for E-Cigarette, or Vaping,Product Use-Associated Lung Injury. N Engl J Med 2020; 382:766.
31. Butt YM, Smith ML, Tazelaar HD, et al. Pathology of Vaping-Associated Lung Injury. N Engl J Med 2019; 381:1780.
32. Thota D, Latham E. Case report of electronic cigarettes possibly associated with eosinophilic pneumonitis in a previously healthy active-duty sailor. J Emerg Med 2014; 47:15.
33. Christiani DC. Vaping-Induced Acute Lung Injury. N Engl J Med 2020; 382:960.
34. Heinzerling A, Armatas C, Karmarkar E, et al. Severe Lung Injury Associated With Use of eCigarette, or Vaping, Products-California, 2019. JAMA Intern Med 2020; 180:861.
35. Blount BC, Karwowski MP, Shields PG, et al. Vitamin E Acetate in Bronchoalveolar-Lavage Fluid Associated with EVALI. N Engl J Med 2020; 382:697.
36. Maddock SD, Cirulis MM, Callahan SJ, et al. Pulmonary Lipid-Laden Macrophages and Vaping. N Engl J Med 2019; 381:1488.
37. Blagev DP, Harris D, Dunn AC, et al. Clinical presentation, treatment, and short-term outcomes of lung injury associated with e-cigarettes or vaping: a prospective observational cohort study. Lancet 2019; 394:2073.
38. Kalininskiy A, Bach CT, Nacca NE, et al. E-cigarette, or vaping, product use associated lung injury (EVALI): case series and diagnostic approach. Lancet Respir Med 2019; 7:1017.
39. Reddy A, Jenssen BP, Chidambaram A, et al. Characterizing e-cigarette vaping-associated lung injury in the pediatric intensive care unit. Pediatr Pulmonol 2021; 56:162.
40. Rao DR, Maple KL, Dettori A, et al. Clinical Features of E-cigarette, or Vaping, Product UseAssociated Lung Injury in Teenagers. Pediatrics 2020; 146.
41. Matta P, Hamati JN, Unno HL, Fox MD. E-cigarette or Vaping Product Use-Associated Lung Injury (EVALI) Without Respiratory Symptoms. Pediatrics 2020; 145.
42. Khanijo S, Lou BX, Makaryus M, et al. Coagulopathy and Inflammatory Dysregulation with ECigarette Use. Am J Med 2020; 133:530.
43. Henry TS, Kanne JP, Kligerman SJ. Imaging of Vaping-Associated Lung Disease. N Engl J Med 2019; 381:1486.
44. Conuel EJ, Chieng HC, Fantauzzi J, et al. Cannabinoid Oil Vaping-Associated Lung Injury and its Radiographic Appearance. Am J Med 2020; 133:865.
45. Reagan-Steiner S, Gary J, Matkovic E, et al. Pathological findings in suspected cases of ecigarette, or vaping, product use-associated lung injury (EVALI): a case series. Lancet Respir Med 2020; 8:1219.
46. Sommerfeld CG, Weiner DJ, Nowalk A, Larkin A. Hypersensitivity Pneumonitis and Acute Respiratory Distress Syndrome From E-Cigarette Use. Pediatrics 2018; 141.
47. Werner AK, Koumans EH, Chatham-Stephens K, et al. Hospitalizations and Deaths
48. Associated with EVALI. N Engl J Med 2020; 382:1589.